Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEQUA in dry eye disease
NCT06482177Phase 4Completed
- Sponsor
- Research Insight
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine ophthalmic solution in dry eye disease (DED), sponsored by Research Insight. Primary endpoint: Change in corneal high order aberrations at 28 days. Started Oct 2023; status: completed.
02
Drugs
cyclosporine ophthalmic solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06482177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482177.